Estimation and enhancement of in vitro corneal transport of S-1033, a novel antiglaucoma medication

Kazutaka Higaki, Masaharu Takeuchi, Masayuki Nakano

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

To improve the in vitro corneal transport of S-1033, a novel prostaglandin-derivative antiglaucoma medication, the effects of several factors such as benzalkonium chloride (BAC), concentration of S-1033, and lipophilicity on the corneal permeability of S-1033 were investigated. The apparent permeability coefficient (P(app)) of S-1033 was 5.81 x 10-7 cm/s on application of 0.1 mM solution. The addition of BAC (0.005%) enhanced by 2.5-fold the transport percent and P(app) of S-1033. Corneal transport tended to be improved by methyl esterification of S-1033 but not by the coexistence of BAC with S-1033 methyl ester. TLC analysis showed that S-1033 methyl ester was hydrolyzed to S-1033 during passage through the cornea. The therapeutic concentration of S-1033 (5.4 mM, the highest concentration in the experiments), greatly promoted its transport and increased P(app). However, there was little difference in the uptake percent, which showed the transcorneal percent and corneal accumulation percent at steady state, for these dosing conditions. The highest concentration gave the lowest corneal accumulation percent and the highest corneal clearance, indicating that the transport rate of S-1033 in the cornea to the receptor side was the largest, which may have been responsible for the marked improvement of the transcorneal transport of S-1033. Increases in corneal accumulation of S-1033 due to methyl esterification and BAC addition seem to be due to the increase of lipophilicity and ion pair formation, respectively. To investigate the relationship between corneal permeability and the partition coefficient (PC) with or without BAC, the permeabilities of prostaglandin F(2α) (PGF(2α)) and prostaglandin E2 (PGE2) were estimated. The larger the value of logPC in the range of - 0.67-3.89, the larger was the value of P(app) in the absence of BAC. However, in the presence of BAC, there was a parabolic relationship, which suggests that BAC can greatly affect the interaction between cornea and drugs.

Original languageEnglish
Pages (from-to)165-173
Number of pages9
JournalInternational Journal of Pharmaceutics
Volume132
Issue number1-2
DOIs
Publication statusPublished - Apr 30 1996
Externally publishedYes

Fingerprint

S 1033
Benzalkonium Compounds
Permeability
Cornea
Esterification
In Vitro Techniques
Esters
Methyl Chloride

Keywords

  • Antiglaucoma medication
  • Benzalkonium chloride
  • Corneal transport
  • Lipophilicity
  • Prostaglandin derivative

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Estimation and enhancement of in vitro corneal transport of S-1033, a novel antiglaucoma medication. / Higaki, Kazutaka; Takeuchi, Masaharu; Nakano, Masayuki.

In: International Journal of Pharmaceutics, Vol. 132, No. 1-2, 30.04.1996, p. 165-173.

Research output: Contribution to journalArticle

@article{f0cf04570ca04f56935fe988e42460a4,
title = "Estimation and enhancement of in vitro corneal transport of S-1033, a novel antiglaucoma medication",
abstract = "To improve the in vitro corneal transport of S-1033, a novel prostaglandin-derivative antiglaucoma medication, the effects of several factors such as benzalkonium chloride (BAC), concentration of S-1033, and lipophilicity on the corneal permeability of S-1033 were investigated. The apparent permeability coefficient (P(app)) of S-1033 was 5.81 x 10-7 cm/s on application of 0.1 mM solution. The addition of BAC (0.005{\%}) enhanced by 2.5-fold the transport percent and P(app) of S-1033. Corneal transport tended to be improved by methyl esterification of S-1033 but not by the coexistence of BAC with S-1033 methyl ester. TLC analysis showed that S-1033 methyl ester was hydrolyzed to S-1033 during passage through the cornea. The therapeutic concentration of S-1033 (5.4 mM, the highest concentration in the experiments), greatly promoted its transport and increased P(app). However, there was little difference in the uptake percent, which showed the transcorneal percent and corneal accumulation percent at steady state, for these dosing conditions. The highest concentration gave the lowest corneal accumulation percent and the highest corneal clearance, indicating that the transport rate of S-1033 in the cornea to the receptor side was the largest, which may have been responsible for the marked improvement of the transcorneal transport of S-1033. Increases in corneal accumulation of S-1033 due to methyl esterification and BAC addition seem to be due to the increase of lipophilicity and ion pair formation, respectively. To investigate the relationship between corneal permeability and the partition coefficient (PC) with or without BAC, the permeabilities of prostaglandin F(2α) (PGF(2α)) and prostaglandin E2 (PGE2) were estimated. The larger the value of logPC in the range of - 0.67-3.89, the larger was the value of P(app) in the absence of BAC. However, in the presence of BAC, there was a parabolic relationship, which suggests that BAC can greatly affect the interaction between cornea and drugs.",
keywords = "Antiglaucoma medication, Benzalkonium chloride, Corneal transport, Lipophilicity, Prostaglandin derivative",
author = "Kazutaka Higaki and Masaharu Takeuchi and Masayuki Nakano",
year = "1996",
month = "4",
day = "30",
doi = "10.1016/0378-5173(95)04372-1",
language = "English",
volume = "132",
pages = "165--173",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Estimation and enhancement of in vitro corneal transport of S-1033, a novel antiglaucoma medication

AU - Higaki, Kazutaka

AU - Takeuchi, Masaharu

AU - Nakano, Masayuki

PY - 1996/4/30

Y1 - 1996/4/30

N2 - To improve the in vitro corneal transport of S-1033, a novel prostaglandin-derivative antiglaucoma medication, the effects of several factors such as benzalkonium chloride (BAC), concentration of S-1033, and lipophilicity on the corneal permeability of S-1033 were investigated. The apparent permeability coefficient (P(app)) of S-1033 was 5.81 x 10-7 cm/s on application of 0.1 mM solution. The addition of BAC (0.005%) enhanced by 2.5-fold the transport percent and P(app) of S-1033. Corneal transport tended to be improved by methyl esterification of S-1033 but not by the coexistence of BAC with S-1033 methyl ester. TLC analysis showed that S-1033 methyl ester was hydrolyzed to S-1033 during passage through the cornea. The therapeutic concentration of S-1033 (5.4 mM, the highest concentration in the experiments), greatly promoted its transport and increased P(app). However, there was little difference in the uptake percent, which showed the transcorneal percent and corneal accumulation percent at steady state, for these dosing conditions. The highest concentration gave the lowest corneal accumulation percent and the highest corneal clearance, indicating that the transport rate of S-1033 in the cornea to the receptor side was the largest, which may have been responsible for the marked improvement of the transcorneal transport of S-1033. Increases in corneal accumulation of S-1033 due to methyl esterification and BAC addition seem to be due to the increase of lipophilicity and ion pair formation, respectively. To investigate the relationship between corneal permeability and the partition coefficient (PC) with or without BAC, the permeabilities of prostaglandin F(2α) (PGF(2α)) and prostaglandin E2 (PGE2) were estimated. The larger the value of logPC in the range of - 0.67-3.89, the larger was the value of P(app) in the absence of BAC. However, in the presence of BAC, there was a parabolic relationship, which suggests that BAC can greatly affect the interaction between cornea and drugs.

AB - To improve the in vitro corneal transport of S-1033, a novel prostaglandin-derivative antiglaucoma medication, the effects of several factors such as benzalkonium chloride (BAC), concentration of S-1033, and lipophilicity on the corneal permeability of S-1033 were investigated. The apparent permeability coefficient (P(app)) of S-1033 was 5.81 x 10-7 cm/s on application of 0.1 mM solution. The addition of BAC (0.005%) enhanced by 2.5-fold the transport percent and P(app) of S-1033. Corneal transport tended to be improved by methyl esterification of S-1033 but not by the coexistence of BAC with S-1033 methyl ester. TLC analysis showed that S-1033 methyl ester was hydrolyzed to S-1033 during passage through the cornea. The therapeutic concentration of S-1033 (5.4 mM, the highest concentration in the experiments), greatly promoted its transport and increased P(app). However, there was little difference in the uptake percent, which showed the transcorneal percent and corneal accumulation percent at steady state, for these dosing conditions. The highest concentration gave the lowest corneal accumulation percent and the highest corneal clearance, indicating that the transport rate of S-1033 in the cornea to the receptor side was the largest, which may have been responsible for the marked improvement of the transcorneal transport of S-1033. Increases in corneal accumulation of S-1033 due to methyl esterification and BAC addition seem to be due to the increase of lipophilicity and ion pair formation, respectively. To investigate the relationship between corneal permeability and the partition coefficient (PC) with or without BAC, the permeabilities of prostaglandin F(2α) (PGF(2α)) and prostaglandin E2 (PGE2) were estimated. The larger the value of logPC in the range of - 0.67-3.89, the larger was the value of P(app) in the absence of BAC. However, in the presence of BAC, there was a parabolic relationship, which suggests that BAC can greatly affect the interaction between cornea and drugs.

KW - Antiglaucoma medication

KW - Benzalkonium chloride

KW - Corneal transport

KW - Lipophilicity

KW - Prostaglandin derivative

UR - http://www.scopus.com/inward/record.url?scp=0029895969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029895969&partnerID=8YFLogxK

U2 - 10.1016/0378-5173(95)04372-1

DO - 10.1016/0378-5173(95)04372-1

M3 - Article

VL - 132

SP - 165

EP - 173

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1-2

ER -